Table 1. Patient and treatment features according to LMR level (n=285).
| Variables | Pretreatment LMR (>5.2), n (%) | Pretreatment LMR (≤5.2), n (%) | P value |
|---|---|---|---|
| Quadrant | 0.807 | ||
| Outer | 99 (55.6) | 61 (57.0) | |
| Upper-inner | 35 (19.7) | 23 (21.5) | |
| Lower-inner/central | 44 (24.7) | 23 (21.5) | |
| Histological grade | 0.056 | ||
| I | 20 (11.2) | 10 (9.3) | |
| II | 151 (84.8) | 85 (79.4) | |
| III | 7 (4.0) | 12 (11.3) | |
| PCR or not | 0.053 | ||
| Yes | 36 (20.2) | 13 (12.1) | |
| No | 142 (79.8) | 94 (88.9) | |
| Surgery | 0.844 | ||
| BCS | 48 (27.0) | 30 (29.2) | |
| MRM | 130 (73.0) | 77 (70.8) | |
| Clinical stage | 0.015 | ||
| II | 81 (45.5) | 37 (34.6) | |
| III | 97 (54.5) | 70 (65.4) | |
| RT | 0.864 | ||
| Yes | 100 (56.2) | 59 (55.1) | |
| No | 78 (43.8) | 48 (44.9) | |
| NAC regimen | 0.193 | ||
| TC | 30 (16.9) | 12 (11.2) | |
| AT | 148 (83.1) | 95 (88.8) | |
| IMN-RT | 0.854 | ||
| Yes | 35 (19.7) | 22 (20.6) | |
| No | 143 (80.3) | 85 (79.4) | |
| Standard endocrine therapy | 0.897 | ||
| Yes | 131 (73.6) | 78 (72.9) | |
| No | 47 (26.4) | 29 (27.1) | |
| Luminal subtype | 0.307 | ||
| Luminal A | 73 (41.0) | 37 (34.6) | |
| Luminal B | 105 (59.0) | 70 (65.4) | |
| Resection margin | |||
| Negative | 164 (92.1) | 97 (90.7) | 0.646 |
| Positive | 14 (7.9) | 10 (9.3) | |
| PR | 0.546 | ||
| Negative | 103 (57.9) | 58 (54.2) | |
| Positive | 75 (42.1) | 49 (45.8) | |
| Pathological stage | 0.682 | ||
| 0–II | 136 (76.4) | 84 (78.5) | |
| III | 42 (23.6) | 23 (21.5) | |
| Age | 0.376 | ||
| >50 | 59 (33.1) | 41 (38.3) | |
| ≤50 | 119 (66.9) | 66 (61.7) |
AT, Doxorubicin Docetaxel BCS, breast-conserving surgery; IMN-RT, internal mammary node radiotherapy; LMR, lymphocyte-to-monocyte ratio; MRM, modified radical mastectomy; NAC, neoadjuvant chemotherapy; pCR, pathological complete response; PR, progesterone receptor; RT, radiation therapy; TC, docetaxel cyclophosphamide.